Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at AACR 2023

– At Week 24, 60mg of Selinexor in Combination with Ruxolitinib Achieved: 92% SVR35 and 78% TSS50 in Efficacy Evaluable Population, 79% SVR35 and 58% TSS50 in...

Related Keywords

Boston ,Massachusetts ,United States ,South Korea ,Singapore ,Germany ,United Kingdom ,Hong Kong ,China ,Canada ,Tsadal ,Kyongsang Bukto ,Taiwan ,Australia ,Israel ,Austria ,American ,Haris Ali ,Reshma Rangwala ,John Mascarenhas ,Linkedin ,American Association For Cancer Research ,Exchange Commission ,Information Department ,Icahn School Of Medicine At Mount Sinai ,Nasdaq ,European Union ,Prnewswire Karyopharm Therapeutics Inc ,Karyopharm Selective Inhibitor Of Nuclear Export ,Drug Administration ,Company To Host Investor Webcast ,City Of Hope Comprehensive Cancer Center ,Karyopharm Therapeutics Inc ,Selective Inhibitor Of Nuclear Export ,Ruxolitinib Achieved ,Efficacy Evaluable Population ,Treat Population ,Sustained Spleen Response Across ,Robust Symptom Improvement ,Generally Tolerable ,Manageable Side Effect Profile ,Recommended Dose ,Initiate Pivotal Phase ,Front Line Myelofibrosis ,Host Investor Webcast ,Key Opinion Leader ,Icahn School ,Mount Sinai ,American Association ,Cancer Research ,Annual Meeting ,Myelofibrosis Symptom Assessment Form ,Chief Medical Officer ,Hope Comprehensive Cancer ,Selinexor Data ,Blood Cancers ,Karyopharm Therapeutics ,Selective Inhibitor ,Nuclear Export ,Prescribing Information ,Medical Information ,Fetal Toxicity ,Private Securities Litigation Reform Act ,Annual Report ,